Table 3.

Serum N4PA biomarker associations with three-year cognitive function score trajectories

Model	Nf-L		GFAP		Total tau		UCHL1
	β (95%CI)	p	β (95%CI)	p	β (95%CI)	p	β (95%CI)	p
3MSE
1	–0.43 (–0.56; –0.30)	<0.001	–0.25 (–0.37; –0.12)	<0.001	–0.05 (–0.17; 0.08)	0.49	0.07 (–0.06; 0.20)	0.29
2	–0.43 (–0.56; –0.30)	<0.001	–0.24 (–0.37; –0.12)	<0.001	–0.05 (–0.17; 0.08)	0.48	0.07 (–0.06; 0.20)	0.28
3	–0.47 (–0.62; –0.31)	<0.001	–0.07 (–0.21; 0.08)	0.36	–0.01 (–0.17; 0.15)	0.90	0.24 (0.08; 0.39)	0.003
DSST
1	–0.33 (–0.51; –0.16)	<0.001	–0.21 (–0.38; –0.03)	0.02	–0.01 (–0.18; 0.17)	0.96	–0.04 (–0.21; 0.14)	0.69
2	–0.33 (–0.51; –0.16)	<0.001	–0.21 (–0.38; –0.04)	0.02	–0.01 (–0.18; 0.16)	0.91	–0.04 (–0.21; 0.14)	0.68
3	–0.34 (–0.55; –0.13)	0.002	–0.07 (–0.27; 0.13)	0.49	0.09 (–0.12; 0.30)	0.38	0.03 (–0.18; 0.24)	0.76

Notes: β represents the protein/time interaction estimate (score change per year per standard deviation log(pg/mL) protein). Model 1 adjusted for age, sex, black race, clinic, and education. Model 2 additionally adjusted for body mass index, waist circumference, smoking status, alcohol consumption status, systolic blood pressure, total cholesterol, fasting plasma glucose, estimated glomerular filtration rate, C- reactive protein, activities of daily living limitation, APOE ε4 carrier status, antihypertensive medication use, lipid lowering medication use, prevalent coronary heart disease, myocardial infarction, stroke, and heart failure. Model 3 additionally included mutual N4PA protein adjustment.

Abbreviations: 3MSE: modified mini-mental status examination; CI, confidence interval; DSST: digit symbol substitution test; GFAP, glial fibrillary acidic protein; Nf-L, neurofilament light chain; UCHL1, ubiquitin carboxyl‐terminal hydrolase L1.